NCT04450004 - Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

September 20, 2020

Study Completion Date

August 30, 2021

Conditions

SARS-CoV 2

Interventions

BIOLOGICAL

Intramuscular Vaccine

Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Trial Locations (2)

Unknown

Syneos Health, Montreal

Syneos Health, Québec